

Remarks


Claims 1-89 are pending in the instant application. Applicants have amended claims 12-16, 18-20, 22, 28, 30, 34-38, 44-45, 52-53, 56, 61, 63, 66, 68, 71, 75, 84 and 88-89 to more fully conform with U.S. practice. Applicants have cancelled claims 57, 59-60, 62, 64, 81 and 86-87, without prejudice and have added new claim 90.

The specification has been amended to insert a cross reference to the related priority applications. Applicants also respectfully request that the attached abstract be added to the specification on a separate sheet as required.

Applicants submit herewith a Sequence Listing, identical to that which was filed during the international stage, on one diskette and on paper totaling four pages. The required statements are also submitted herewith totaling two pages.

Applicants respectfully assert that all amendments are fairly based on the specification, and respectfully request their entry. Applicants believe that the claims, as amended, are in allowable form and earnestly solicited the allowance of claims 1-56, 58, 61, 63, 65-80, 82-85 and 88-90.

Respectfully submitted,


Royal N. Ronning, Jr.
Registration No.: 32,529
Attorney for Applicants

Customer No.: 22840

Amersham Biosciences Corp
Patent Department
800 Centennial Avenue
Piscataway, New Jersey 08855-1327

Tel: (732) 457-8423
Fax: (732) 457-8463